BioTime Announces Stock Ticker Symbol Change and Extension of Warrant Expiration Date
October 12 2010 - 8:00AM
Business Wire
BioTime, Inc. (NYSE Amex:BTIM). BioTime announced today the
change of its stock ticker symbol on the NYSE Amex. Additionally,
BioTime announced today that it is extending the expiration date of
its common share purchase warrants that expire on October 31,
2010.
BioTime announced that commencing November 2, 2010, the trading
symbol of its common shares on the NYSE Amex will change from BTIM
to BTX.
Because October 31 is a Sunday, BioTime is extending the warrant
expiration date and time until 5:00 p.m. New York time on Monday,
November 1, 2010. Trading of the warrants on the NYSE Amex will
continue through October 29, 2010.
BioTime will permit exercises of the warrants to be accepted by
the warrant agent through a notice of guaranteed delivery from a
bank, a trust company, or a New York Stock Exchange member
guaranteeing delivery of a properly completed and executed warrant
certificate. Warrant holders who choose to exercise their warrants
through a notice of guaranteed delivery must pay the exercise price
of their warrants and must deliver the notice of guaranteed
delivery to the warrant agent by facsimile telecopy or otherwise
not later than 5:00 p.m. New York time on Monday, November 1, 2010.
The warrant agent will not honor a notice of guaranteed delivery
unless the warrant agent receives payment of the exercise price of
the warrants and the notice of guaranteed delivery by 5:00 p.m. New
York time on the warrant expiration date, and the warrant agent
receives a properly completed and executed warrant certificate by
the close of business (5:00 p.m. New York time) on the third
business day after the warrant expiration date.
Warrant holders who desire to exercise their warrants should
deliver their properly completed warrant certificates and notices
of guaranteed delivery to the Warrant Agent, American Stock
Transfer & Trust Company, by hand, mail, express mail, or
overnight courier at the following address:
American Stock Transfer & Trust Company Attn: Reorganization
Department 6201 15th Avenue Brooklyn, New York 11219
Notices of Guaranteed Deliver (but not warrant certificates) may
also be delivered to the Warrant Agent by facsimile at (718)
234-5001. All facsimile transmissions should be confirmed by
contacting the Warrant Agent by telephone at 1-877-248-6417.
BioTime suggests that you send funds for the payment of the
warrant exercise price by wire transfer to American Stock Transfer
& Trust Company, Warrant Agent, JP Morgan Chase Bank WIRE
CLEARING ACCOUNT ABA #021000021, Account 530354624, Attention:
Reorg. Dept.
Do not send warrant certificates or notices of guaranteed
delivery to BioTime.
The securities described in this communication may only be
offered by means of a prospectus. This communication shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a
biotechnology company focused on regenerative medicine and blood
plasma volume expanders. Its broad platform of stem cell
technologies is developed through subsidiaries focused on specific
fields of applications. BioTime develops and markets research
products in the field of stem cells and regenerative medicine
through its wholly owned subsidiary Embryome Sciences, Inc.
BioTime’s therapeutic product development strategy is pursued
through subsidiaries that focus on specific organ systems and
related diseases for which there is a high unmet medical need.
BioTime’s majority owned subsidiary Cell Cure Neurosciences, Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic
applications of stem cells to treat orthopedic diseases and
injuries. Another subsidiary, OncoCyte Corporation, focuses on the
therapeutic applications of stem cell technology in cancer.
BioTime’s Singapore subsidiary, ES Cell International Pte Ltd, has
been at the forefront of advances in human embryonic stem (“hES”)
cell technology, having been one of the earliest distributors of
hES cell lines to the research community. ESI has produced
clinical-grade human embryonic stem cell lines that were derived
following principles of good manufacturing practice and currently
offers them for potential use in therapeutic product development.
In addition to its stem cell products, BioTime develops blood
plasma volume expanders, blood replacement solutions for
hypothermic (low temperature) surgery, and technology for use in
surgery, emergency trauma treatment and other applications.
BioTime’s lead product, Hextend®, is a blood plasma volume expander
manufactured and distributed in the U.S. by Hospira, Inc. and in
South Korea by CJ CheilJedang Corp. under exclusive licensing
agreements. Additional information about BioTime, Embryome
Sciences, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, and ESI can
be found on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for the company and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the company’s business,
particularly those mentioned in the cautionary statements found in
the company’s Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0